Skip to main content
TipRanks
Go Ultimate75% OFF

Corvus Pharmaceuticals (CRVS) Stock Statistics & Valuation Metrics

715 Followers

Total Valuation

Corvus Pharmaceuticals has a market cap or net worth of $844.37M. The enterprise value is $863.15M.

Market Cap
$844.37M
Enterprise Value
$863.15M

Share Statistics

Corvus Pharmaceuticals has 84,353,130 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
84,353,130
Owned by Insiders
13.80%
Owned by Institutions
74.31%

Financial Efficiency

Corvus Pharmaceuticals’s return on equity (ROE) is -0.25 and return on invested capital (ROIC) is -69.15%.

Return on Equity (ROE)
-0.25
Return on Assets (ROA)
-0.21
Return on Invested Capital (ROIC)
-69.15%
Return on Capital Employed (ROCE)
-0.70
Revenue Per Employee
0
Profits Per Employee
-413.05K
Employee Count
37
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Corvus Pharmaceuticals is -13.53. Corvus Pharmaceuticals’s PEG ratio is 0.08.

PE Ratio
-13.53
PS Ratio
0.00
PB Ratio
4.44
Price to FCF
-17.61
Price to Operating Cash Flow
-19.62
PEG Ratio
0.08

Income Statement

In the last 12 months, Corvus Pharmaceuticals had revenue of 0 and earned -15.28M in profits. Earnings per share was -0.19.

Revenue
0
Gross Profit
-105.00K
Operating Income
-42.97M
Pretax Income
-15.28M
Net Income
-15.28M
EBITDA
-15.18M
Earnings Per Share (EPS)
-0.19

Cash Flow

In the last 12 months, operating cash flow was -47.18M and capital expenditures -764,000, giving a free cash flow of -47.94M billion.

Operating Cash Flow
-47.18M
Free Cash Flow
-47.94M
Free Cash Flow per Share
-0.52

Dividends & Yields

Corvus Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-5.62%
Earnings Yield
-6.87%

Stock Price Statistics

Beta
0.93
52-Week Price Change
12.47%
50-Day Moving Average
11.03
200-Day Moving Average
13.79
Relative Strength Index (RSI)
42.95
Average Volume (3m)
1.04M

Important Dates

Corvus Pharmaceuticals upcoming earnings date is Mar 24, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 05, 2026
Next Earnings Date
Mar 24, 2027
Ex-Dividend Date
―

Financial Position

Corvus Pharmaceuticals as a current ratio of 6.21, with Debt / Equity ratio of 1.53%

Current Ratio
6.21
Quick Ratio
6.21
Debt to Market Cap
0.00
Net Debt to EBITDA
0.24
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Corvus Pharmaceuticals has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Corvus Pharmaceuticals EV to EBITDA ratio is -13.55, with an EV/FCF ratio of -17.51.

EV to Sales
0.00
EV to EBITDA
-13.55
EV to Free Cash Flow
-17.51
EV to Operating Cash Flow
-17.79

Balance Sheet

Corvus Pharmaceuticals has $202.95M in cash and marketable securities with $632.00K in debt, giving a net cash position of $202.31M billion.

Cash & Marketable Securities
$202.95M
Total Debt
$632.00K
Net Cash
$202.31M
Net Cash Per Share
$2.40
Tangible Book Value Per Share
$2.25

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin
0.00%
Operating Margin
0.00%
Pretax Margin
0.00%
Net Profit Margin
0.00%
EBITDA Margin
0.00%
EBIT Margin
0.00%

Analyst Forecast

The average price target for Corvus Pharmaceuticals is $28.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
$28.75
Price Target Upside
187.21% Upside
Analyst Consensus
Strong Buy
Analyst Count
4
Revenue Growth Forecast
―
EPS Growth Forecast
-272.40%

Scores

Smart Score
8
AI Score
51